SciCombinator

Discover the most talked about and latest scientific content & concepts.

O Kavanagh, A Marie Healy, F Dayton, S Robinson, NJ O'Reilly, B Mahoney, A Arthur, G Walker and JP Farragher
Abstract
Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.
Tweets*
407
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
0
Concepts
-
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com